CO6150140A2 - Inhibidores de proteina tirosina fosfatasa humana y metodos de uso - Google Patents
Inhibidores de proteina tirosina fosfatasa humana y metodos de usoInfo
- Publication number
- CO6150140A2 CO6150140A2 CO09007334A CO09007334A CO6150140A2 CO 6150140 A2 CO6150140 A2 CO 6150140A2 CO 09007334 A CO09007334 A CO 09007334A CO 09007334 A CO09007334 A CO 09007334A CO 6150140 A2 CO6150140 A2 CO 6150140A2
- Authority
- CO
- Colombia
- Prior art keywords
- substituted
- unsubstituted
- branched
- alkyl
- linear
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
Abstract
1.- Un compuesto que tiene la fórmula:en donde R es una unidad tiazolilo sustituida o no sustituida que tiene la fórmula:R2 y R3 se escogen cada uno independientemente de:hidrógeno; ii) alquilo C1-C6 lineal, ramificado o cíclico sustituido o no sustituido; iii) fenilo sustituido o no sustituido; iv) heteroarilo sustituido o no sustituido; o R2 y R3 se pueden tomar juntos para formar un anillo saturado o insaturado que tiene de 5 a 7 átomos; dichas sustituciones se escogen independientemente de uno o más unidades alquilo C1-C6 lineal, cíclico o ramificado, halógeno, hidroxilo, o ciano; R4 es una unidad escogida de: i) hidrógeno; ii) alquilo C1-C6 lineal, ramificado o cíclico sustituido o no sustituido; iii) fenilo sustituido o no sustituido; y iv) heteroarilo sustituido o no sustituido; Z es una unidad que tiene la fórmula:R1 se escoge de: i) hidrógeno; ii) alquilo C1-C6 lineal, ramificado o sustituido o no sustituido; iii) arilo sustituido o no sustituido; anillos heterocíclicos sustituidos y no sustituidos; o anillos heteroarilo, sustituidos o no sustituidos; L es una unidad de enlace escogida de: i) -C(O)NH[C(R5aR5b)w-; ii) -C(O)(C(R6aR6b]x-; iii) -C(O)[C(R7aR7b]yC(O)-; iv) -SO2[C(R8aR8b)]z-;R5a, R5b, R6a, R6b, R7a, R7b, R8a, y R8b son cada uno independientemente: i) hidrógeno; ii) alquilo C1-C4 lineal o ramificado sustituido o no sustituido; iiii) arilo sustituido o no sustituido; iv) anillos heterocíclicos sustituidos y no sustituidos; v) anillos heteroarilo sustituidos o no sustituidos; el índice n es 0 o 1; los índices w, x, y, y z son cada uno independientemente de 1 a 4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81673106P | 2006-06-27 | 2006-06-27 | |
US81682506P | 2006-06-27 | 2006-06-27 | |
US81673006P | 2006-06-27 | 2006-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6150140A2 true CO6150140A2 (es) | 2010-04-20 |
Family
ID=38704715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09007334A CO6150140A2 (es) | 2006-06-27 | 2009-01-27 | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso |
Country Status (20)
Country | Link |
---|---|
US (3) | US7795444B2 (es) |
EP (3) | EP2038265B1 (es) |
JP (6) | JP5261383B2 (es) |
KR (1) | KR101179087B1 (es) |
AU (1) | AU2007265454B2 (es) |
BR (1) | BRPI0713357A2 (es) |
CA (1) | CA2657107C (es) |
CO (1) | CO6150140A2 (es) |
CY (1) | CY1116377T1 (es) |
DK (1) | DK2038265T3 (es) |
ES (1) | ES2534392T3 (es) |
HK (1) | HK1129387A1 (es) |
HU (1) | HUE024976T2 (es) |
IL (1) | IL196129A (es) |
MX (1) | MX2009000289A (es) |
NZ (1) | NZ574406A (es) |
PL (1) | PL2038265T3 (es) |
PT (1) | PT2038265E (es) |
SI (1) | SI2038265T1 (es) |
WO (1) | WO2008002570A2 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226755B1 (en) * | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7507568B2 (en) * | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
WO2007116360A2 (en) | 2006-04-07 | 2007-10-18 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
US20130023542A1 (en) * | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7795444B2 (en) * | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) * | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
AU2016203254B2 (en) * | 2009-01-12 | 2018-09-13 | EyePoint Pharmaceuticals, Inc. | Methods for treating vascular leak syndrome |
AU2014202211B2 (en) * | 2009-01-12 | 2016-06-02 | EyePoint Pharmaceuticals, Inc. | Methods for treating vascular leak syndrome |
RU2014146121A (ru) * | 2009-01-12 | 2015-06-10 | Аэрпио Терапьютикс Инк. | Способы лечения синдрома сосудистой утечки |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
BRPI1006897A2 (pt) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compostos, composições e métodos de prevenção da metástase de células cancerosas. |
AU2010314973B9 (en) | 2009-11-06 | 2015-03-19 | Aerpio Therapeutics Inc. | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
CA2890554A1 (en) * | 2010-10-07 | 2012-04-12 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular edema, neovascularization and related diseases |
US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
EP2766044B1 (en) | 2011-10-13 | 2019-12-11 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
JP5941598B2 (ja) * | 2013-01-09 | 2016-06-29 | ギリアード サイエンシーズ, インコーポレイテッド | 5員ヘテロアリールおよびそれらの抗ウイルス剤としての使用 |
WO2014113407A2 (en) | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
WO2014145068A1 (en) * | 2013-03-15 | 2014-09-18 | Aerpio Therapeutics Inc. | Compositions, formulations and methods for treating ocular diseases |
JP6549140B2 (ja) | 2014-02-19 | 2019-07-24 | エアーピオ セラピューティクス インコーポレイテッド | N−ベンジル−3−ヒドロキシ−4−置換ピリジン−2−(1h)−オン |
US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
JP6746614B2 (ja) * | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
AU2016326510C1 (en) | 2015-09-23 | 2024-06-27 | EyePoint Pharmaceuticals, Inc. | Methods of treating intraocular pressure with activators of Tie-2 |
JP6690282B2 (ja) | 2016-02-15 | 2020-04-28 | 住友電気工業株式会社 | 炭化珪素エピタキシャル基板および炭化珪素半導体装置の製造方法 |
EP3487518A4 (en) | 2016-07-20 | 2020-08-12 | Aerpio Therapeutics LLC | HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS) |
JP2022502367A (ja) | 2018-09-24 | 2022-01-11 | エアーピオ ファーマシューティカルズ, インコーポレイテッド | HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体 |
WO2020223209A1 (en) | 2019-04-29 | 2020-11-05 | Aerpio Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
GB2589400A (en) | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
US11613534B2 (en) | 2019-10-29 | 2023-03-28 | EyePoint Pharmaceuticals, Inc. | Small molecule activators of Tie-2 |
JP2023530457A (ja) * | 2020-06-16 | 2023-07-18 | リプカ,エイミー | 小分子ve-ptp阻害剤 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4673641A (en) | 1982-12-16 | 1987-06-16 | Molecular Genetics Research And Development Limited Partnership | Co-aggregate purification of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE69332197T2 (de) | 1992-03-13 | 2003-04-17 | Organon Teknika Bv | Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten |
US5770565A (en) | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
US5688781A (en) * | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
AR022303A1 (es) * | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
WO2000065088A2 (en) | 1999-04-26 | 2000-11-02 | Amersham Pharmacia Biotech Ab | Primers for identifying typing or classifying nucleic acids |
BR0010017A (pt) | 1999-04-28 | 2002-06-11 | Univ Texas | Composições e processos para o tratamento de câncer por inibição seletiva de vegf |
WO2000070030A1 (en) | 1999-05-19 | 2000-11-23 | Amgen Inc. | Crystal of a lymphocyte kinase-ligand complex and methods of use |
ES2252058T3 (es) | 1999-08-27 | 2006-05-16 | Sugen, Inc. | Mimicos de fosfato y metodos de tratamiento empleando inhibidores de fosfatasa. |
US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
JP2004509974A (ja) | 2000-09-27 | 2004-04-02 | ザ プロクター アンド ギャンブル カンパニー | メラノコルチンの受容体リガンド |
AU2003222127A1 (en) * | 2002-03-29 | 2003-10-13 | Ontogen Corporation | Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases |
US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
US20040167183A1 (en) * | 2003-02-20 | 2004-08-26 | The Procter & Gamble Company | Phenethylamino sulfamic acids |
US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
WO2007116360A2 (en) | 2006-04-07 | 2007-10-18 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
US7795444B2 (en) * | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) * | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7769557B2 (en) * | 2008-07-01 | 2010-08-03 | Honeywell International Inc. | Multi-gas flow sensor with gas specific calibration capability |
RU2014146121A (ru) | 2009-01-12 | 2015-06-10 | Аэрпио Терапьютикс Инк. | Способы лечения синдрома сосудистой утечки |
BRPI1006897A2 (pt) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compostos, composições e métodos de prevenção da metástase de células cancerosas. |
-
2007
- 2007-06-26 US US11/821,846 patent/US7795444B2/en active Active
- 2007-06-27 SI SI200731650T patent/SI2038265T1/sl unknown
- 2007-06-27 EP EP07809908.2A patent/EP2038265B1/en active Active
- 2007-06-27 BR BRPI0713357-0A patent/BRPI0713357A2/pt not_active Application Discontinuation
- 2007-06-27 NZ NZ574406A patent/NZ574406A/en not_active IP Right Cessation
- 2007-06-27 EP EP12196179.1A patent/EP2592073B1/en active Active
- 2007-06-27 ES ES07809908.2T patent/ES2534392T3/es active Active
- 2007-06-27 WO PCT/US2007/014823 patent/WO2008002570A2/en active Application Filing
- 2007-06-27 PL PL07809908T patent/PL2038265T3/pl unknown
- 2007-06-27 CA CA2657107A patent/CA2657107C/en active Active
- 2007-06-27 JP JP2009518227A patent/JP5261383B2/ja not_active Expired - Fee Related
- 2007-06-27 MX MX2009000289A patent/MX2009000289A/es active IP Right Grant
- 2007-06-27 DK DK07809908.2T patent/DK2038265T3/en active
- 2007-06-27 AU AU2007265454A patent/AU2007265454B2/en not_active Ceased
- 2007-06-27 HU HUE07809908A patent/HUE024976T2/en unknown
- 2007-06-27 PT PT78099082T patent/PT2038265E/pt unknown
- 2007-06-27 KR KR1020097001694A patent/KR101179087B1/ko active IP Right Grant
- 2007-06-27 EP EP17187910.9A patent/EP3293182A1/en not_active Withdrawn
-
2008
- 2008-12-23 IL IL196129A patent/IL196129A/en active IP Right Grant
-
2009
- 2009-01-27 CO CO09007334A patent/CO6150140A2/es unknown
- 2009-09-10 HK HK09108320.5A patent/HK1129387A1/xx not_active IP Right Cessation
-
2010
- 2010-08-04 US US12/850,026 patent/US8106078B2/en not_active Expired - Fee Related
-
2011
- 2011-12-01 US US13/309,445 patent/US8329916B2/en active Active
-
2013
- 2013-02-19 JP JP2013029649A patent/JP2013091669A/ja not_active Withdrawn
-
2015
- 2015-05-08 CY CY20151100409T patent/CY1116377T1/el unknown
- 2015-09-10 JP JP2015178321A patent/JP2015221837A/ja active Pending
- 2015-09-10 JP JP2015178320A patent/JP2016026176A/ja not_active Withdrawn
-
2017
- 2017-11-06 JP JP2017213854A patent/JP2018048190A/ja not_active Withdrawn
- 2017-11-06 JP JP2017213855A patent/JP2018016657A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6150140A2 (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso | |
CO6150144A2 (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso | |
AR020551A2 (es) | Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos. | |
CO5690577A2 (es) | Derivados de imidazoquinolina como ligandos receptores de adenosina a3 | |
ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
PE20050338A1 (es) | Compuestos de aminotriazoles como inhibidores de proteina quinasas | |
AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
NI201000130A (es) | Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica. | |
PE20140961A1 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
CO6160231A2 (es) | Compuestos de isoindolina 5-substituidos | |
AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
CO6210721A2 (es) | Acilaminopirazoles como inhibidores de fgfr | |
CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
AR060590A1 (es) | Compuestos imidazo | |
ECSP055974A (es) | Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
AR061134A1 (es) | Derivados de tioxantina | |
AR060591A1 (es) | Compuestos imidazo | |
AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
WO2008007122A3 (en) | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's | |
DE602007004740D1 (de) | Antibiotische spiroderivate | |
CO6321266A2 (es) | Inhibidores limk2 compuestos de los cuales estan hechos y metodologia de uso | |
CO5700768A2 (es) | Derivados de benzoxazina y sus usos | |
CO6220950A2 (es) | Compuestos heterociclicos compuestos que los comprenden y metodos para su uso | |
ECSP099351A (es) | Compuestos heterociclicos y su uso como inhibidores de la |